Edition:
India

People: ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

55.86USD
25 Nov 2020
Change (% chg)

-- (--)
Prev Close
$55.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
451,921
52-wk High
$58.67
52-wk Low
$30.02

Daly, James 

Mr. James Michael Daly serves as Independent Director of the Company. Mr. Daly has served as a director of our company since January 2016. Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from October 2012 to June 2015. Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for 10 years, holding multiple leadership positions. In his last role, Mr. Daly served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®. Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®. He currently serves on the boards of directors of argenx SE, Bellicum Pharmaceuticals, Inc., Halozyme Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc. Mr. Daly previously served on the board of directors of Chimerix Inc. Mr. Daly earned his B.S. in pharmacy and M.B.A. from the University at Buffalo, The State University of New York. The NCG Committee believes that Mr. Daly’s deep experience as a pharmaceutical executive enables him to bring critical industry and commercial knowledge and leadership skills to the Board.

Basic Compensation

Total Annual Compensation, USD 70,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 322,439
Fiscal Year Total, USD 392,439

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stephen Biggar

319,959

Srdjan Stankovic

5,088,270

Stephen Davis

7,631,250

Elena Ridloff

1,990,870

Austin Kim

1,906,130

Gudarz Davar

--
As Of  31 Dec 2019